

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human LRRC15 in direct ELISA.
Source	Recombinant Monoclonal Rabbit IgG Clone # 2944A
Purification	Protein A or G purified from cell culture supernatant
Immunogen	Chinese Hamster Ovary cell line, CHO-derived human LRRC15 Met1-Gly538 Accession # Q8TF66
Conjugate	Alexa Fluor 647 Excitation Wavelength: 650 nm Emission Wavelength: 668 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Flow Cytometry	Titration recommended for optimal concentration with starting range of 0.1-1 µg/1 million cells. Sample used for this experiment was HEK293 cells transfected with Human LRRC-15 and eGFP.
-----------------------	--

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

LRRC15 is a type-I 15-leucine-rich repeat containing membrane protein that is located on chromosome 3 at 3q29. It is a 581 aa membrane protein that belong to the LRR superfamily and lacks an intracellular signaling domain. Reports indicate that it is highly expressed on cancer-associated fibroblasts in numerous solid tumors, and in the epithelial cancer cell compartment of glioblastoma, sarcomas and melanoma tumors. LRRC15 functions by regulating cell-cell and cell-extracellular matrix (ECM) interactions, likely partnering with fibronectin, laminin and collagen IV through its extracellular leucine-rich repeats. LRRC15 is reported in multiple solid tumor types including breast, ovarian and cervical cancers where it exhibits Increased stromal expression (1). Recent studies indicate that LRRC15 is co-expressed with COL10A1, a gene that is overexpressed in many types of solid tumors, including breast cancer (2).

References:

1. Cancer Res. 2022 March 15; **82(6)**: 1038. doi:10.1158/0008-5472.CAN-21-0622.
2. Biosci Rep. 2020 Feb 28; **40(2)**: BSR20193286. doi: 10.1042/BSR20193286.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.